118 related articles for article (PubMed ID: 3572202)
1. Antithrombin III loss in patients with nephrotic syndrome or receiving continuous ambulatory peritoneal dialysis. Evidence of inactive antithrombin III in urine of patients with nephrotic syndrome.
De Stefano V; Triolo L; De Martini D; Ferrelli R; Mori R; Leone G
J Lab Clin Med; 1987 May; 109(5):550-5. PubMed ID: 3572202
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels and loss of antithrombin III in chronic ambulatory peritoneal dialysis and nephrotic patients.
Mori R; Triolo L; De Stefano V; Giusti BP; De Sole P; Leone G
Nephron; 1988; 48(3):213-6. PubMed ID: 3352848
[TBL] [Abstract][Full Text] [Related]
3. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
Grau E; Oliver A; Félez J; Barceló P; Fernandez C; Ballarin JA; Fontcuberta J; Rutllant ML
Thromb Haemost; 1988 Oct; 60(2):137-40. PubMed ID: 3217913
[TBL] [Abstract][Full Text] [Related]
4. [Plasma and urinary antithrombin III in the nephrotic syndrome in adults].
Antelin CH; Gouault-Heilmann M; Levent M; Bernard D; Ruszniewski P; Lagrue G
Ann Med Interne (Paris); 1983; 134(8):713-6. PubMed ID: 6666909
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin III in full-term and pre-term newborn infants: three cases of neonatal diagnosis of AT III congenital defect.
De Stefano V; Leone G; De Carolis MP; Ferrelli R; De Carolis S; Pagano L; Tortorolo G; Bizzi B
Thromb Haemost; 1987 Jun; 57(3):329-31. PubMed ID: 3660333
[TBL] [Abstract][Full Text] [Related]
6. Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities.
De Stefano V; Leone G; Mastrangelo S; Lane DA; Girolami A; de Moerloose P; Sas G; Abildgaard U; Blajchman M; Rodeghiero F
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):7-15. PubMed ID: 8180341
[TBL] [Abstract][Full Text] [Related]
7. High plasma levels of protein C activity and antigen in the nephrotic syndrome.
Mannucci PM; Valsecchi C; Bottasso B; D'Angelo A; Casati S; Ponticelli C
Thromb Haemost; 1986 Feb; 55(1):31-3. PubMed ID: 3754658
[TBL] [Abstract][Full Text] [Related]
8. Further characterization of a pathological isoantithrombin with no affinity for heparin (antithrombin III Roma).
De Stefano V; Leone G; Ferrelli R; Di Donfrancesco A; De Martini D; Bizzi B
Thromb Res; 1987 Oct; 48(1):23-30. PubMed ID: 3424283
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin III molecular variants with defective binding to heparin or to serine proteases: evidence of two different abnormal patterns identified by crossed immunoelectrofocusing.
Leone G; De Stefano V; Ferrelli R; Teofili L; Tengborn L; Vahtera E; Bizzi B
Thromb Haemost; 1988 Aug; 60(1):8-12. PubMed ID: 3187949
[TBL] [Abstract][Full Text] [Related]
10. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome.
Vaziri ND; Paule P; Toohey J; Hung E; Alikhani S; Darwish R; Pahl MV
Arch Intern Med; 1984 Sep; 144(9):1802-3. PubMed ID: 6477000
[TBL] [Abstract][Full Text] [Related]
11. Is there a link between CD146, a novel adhesion molecule and other markers of endothelial dysfunction in nephrotic syndrome and continuous ambulatory peritoneal dialysis?
Małyszko J; Małyszko JS; Myśliwiec M
Thromb Res; 2005; 115(1-2):19-24. PubMed ID: 15567448
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Choi KC; Jeong TK; Lee SC; Kim SW; Kim NH; Lee KY
Adv Perit Dial; 1998; 14():173-9. PubMed ID: 10649719
[TBL] [Abstract][Full Text] [Related]
13. AT III Barcelona: a familial quantitative-qualitative AT III deficiency.
Grau E; Fontcuberta J; Félez J; de Diego I; Soto R; Rutllant ML
Thromb Haemost; 1988 Feb; 59(1):13-7. PubMed ID: 3363529
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III metabolism in two patients with a nephrotic syndrome caused by minimal chain nephritis and primary amyloidosis.
Drijfhout HH; Knot EA; ten Cate JW
Haemostasis; 1987; 17(5):286-92. PubMed ID: 3666586
[TBL] [Abstract][Full Text] [Related]
15. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
Jørgensen M; Petersen LC; Thorsen S
J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal fibrin-formation and its inhibition in CAPD.
Gries E; Paar D; Graben N; Bock KD
Clin Nephrol; 1986 Oct; 26(4):209-12. PubMed ID: 3780071
[TBL] [Abstract][Full Text] [Related]
18. Immunoquantitation of Hageman factor in urine and plasma of children with nephrotic syndrome.
Hruby MA; Honig GR; Shapira E
J Lab Clin Med; 1980 Sep; 96(3):501-10. PubMed ID: 6772722
[TBL] [Abstract][Full Text] [Related]
19. Successful kidney transplantation does not reverse the coagulopathy in patients with chronic renal failure on either hemo or peritoneal dialysis.
Ballow A; Gader AM; Huraib S; Mitwalli A; Al-Suleimani F; Al-Wakeel J
Saudi J Kidney Dis Transpl; 2007 Jun; 18(2):177-85. PubMed ID: 17496391
[TBL] [Abstract][Full Text] [Related]
20. Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients.
Thompson AR
Thromb Haemost; 1982 Aug; 48(1):27-32. PubMed ID: 6813992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
